Key points are not available for this paper at this time.
This NMA's results indicate that commercially available JAKinibs show superior ACR responses and have comparable tolerability to placebo.
Almoallim et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: